CLLS — Cellectis S.A.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1627281 ·
France
Last close
$1.06
Market Cap
$77.08M
52W High
$5.45
52W Low
$0.88
ADV30
94,181
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 3,764,000 | 1,271,000 | -66,918,000 | -61,474,000 | 213,425,000 | 28,229,000 | 231,057,000 |
| Jun 2026 | 5,229,000 | 2,874,000 | -23,520,000 | -21,819,000 | 267,365,000 | 35,590,000 | 226,298,000 |
| Mar 2026 | 5,777,000 | 3,457,000 | -25,168,000 | -17,765,000 | 289,187,000 | 34,841,000 | 229,267,000 |
| Dec 2025 | 10,396,000 | 7,397,000 | -17,351,000 | -26,318,000 | 324,720,000 | 61,533,000 | 248,819,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-41,627,000
Investing CF
$31,558,000
Financing CF
$-16,553,000
CapEx
$-3,351,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.65
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-303,928,000
Inventory
—
Receivables
$13,644,000
ST Investments
$131,257,000
EBIT TTM
$-57,583,000
Pretax Income TTM
$-65,665,000
Interest Exp TTM
$8,082,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$63,823,000
EBITDA
$-46,677,000
Free Cash Flow
$107,701,376
Enterprise Value
$139,028,288
Total Cash
$166,686,000
Total Debt
$80,350,000
Shares Out
72,718,974
Trailing EPS
$-0.64
Book Value
$0.56
ROE
-94.5%
ROA
-11.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 72,949,000 | -33,076,000 | -67,593,000 | 324,720,000 | 248,819,000 | 75,901,000 | -39,401,000 |
| Dec 2024 | 41,506,000 | -59,554,000 | -36,761,000 | 383,544,000 | 252,511,000 | 131,033,000 | 22,989,000 |
| Dec 2023 | 755,000 | -97,303,000 | -101,059,000 | 334,270,000 | 249,575,000 | 84,695,000 | -24,746,000 |
| Dec 2022 | 19,171,000 | -89,666,000 | -106,139,000 | 261,216,000 | 135,275,000 | 117,968,000 | -87,444,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.62
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CHRS | Coherus Oncology, Inc. | $73.95M | $0.48 | — |
| TNYA | Tenaya Therapeutics, Inc. | $73.58M | $0.32 | — |
| BDTX | Black Diamond Therapeutics, Inc. | $82.75M | $1.44 | — |
| VXRT | Vaxart, Inc. | $86.51M | $0.35 | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $68.60M | $0.74 | — |
News headlines (Yahoo Finance, 1h cache)
Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene Editing ...
2026-11-13 23:03 · Yahoo
What Cellectis (CLLS) Said on Its Q3 Earnings Call
2026-11-13 15:14 · Yahoo
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
2026-11-13 00:24 · Yahoo
Cellectis to Report Third Quarter Financial Results on November 12, 2026
2026-11-09 21:30 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline Slightly in Tuesday Trading
2026-11-03 16:23 · Yahoo
Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
2026-10-27 07:15 · Yahoo
European Equities Traded in the US as American Depositary Receipts Tumble in Tuesday Trading
2026-11-17 16:20 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise Marginally in Friday Trading
2026-11-13 16:17 · Yahoo
European Equities Traded in the US as ADRs Tick Higher in Wednesday Trading
2026-11-11 16:12 · Yahoo
Monthly information on share capital and company voting rights
2026-11-04 21:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.